Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Transcode Therapeutics Inc RNAZ

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.


NDAQ:RNAZ - Post by User

User Avatar Image
(295)
•••
  • whytestocksX
Post by whytestockson Jul 13, 2023 6:00pm
42 Views
Post# 35540262

Stonegate Healthcare Partners Announces Publishing of a Them

Stonegate Healthcare Partners Announces Publishing of a Them
News; $RNAZ Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAiStonegate Healthcare's research approach centers on conducting a thorough comparative analysis to identify potentially revolutionary assets and technologies. Dallas, Texas--(Newsfile Corp. - July 13, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased t...RNAZ - Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi

<< Previous
Bullboard Posts
Next >>